A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-018-0387-x
Abstract: BackgroundPreclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to… read more here.
Keywords: vemurafenib patients; patients braf; braf v600; cohort ... See more keywords